Last update 21 Nov 2024
Recombinant anti-VEGF humanized monoclonal antibody(Shanghai Fudan Zhangjiang Bio Pharmaceutical Co. Ltd.)
Last update 21 Nov 2024
Overview
Basic Info
Drug Type Monoclonal antibody |
Synonyms- |
Target |
Mechanism VEGF inhibitors(Vascular endothelial growth factor inhibitors) |
Therapeutic Areas |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePhase 3 |
First Approval Date- |
Regulation- |
Login to view timeline
Related
2
Clinical Trials associated with Recombinant anti-VEGF humanized monoclonal antibody(Shanghai Fudan Zhangjiang Bio Pharmaceutical Co. Ltd.)随机、双盲、平行对照比较重组抗VEGF注射液和安维汀治疗非鳞状细胞非小细胞肺癌患者疗效和安全性Ⅲ期临床研究
[Translation] A randomized, double-blind, parallel controlled phase III clinical study to compare the efficacy and safety of recombinant anti-VEGF injection and Avastin in the treatment of patients with non-squamous non-small cell lung cancer
比较重组抗VEGF人源化单克隆抗体注射液与贝伐珠单抗注射液在健康男性中 药代动力学和安全性的相似性的I期临床研究
[Translation] A phase I clinical study comparing the pharmacokinetics and safety of recombinant anti-VEGF humanized monoclonal antibody injection and bevacizumab injection in healthy men
100 Clinical Results associated with Recombinant anti-VEGF humanized monoclonal antibody(Shanghai Fudan Zhangjiang Bio Pharmaceutical Co. Ltd.)
Login to view more data
100 Translational Medicine associated with Recombinant anti-VEGF humanized monoclonal antibody(Shanghai Fudan Zhangjiang Bio Pharmaceutical Co. Ltd.)
Login to view more data
100 Patents (Medical) associated with Recombinant anti-VEGF humanized monoclonal antibody(Shanghai Fudan Zhangjiang Bio Pharmaceutical Co. Ltd.)
Login to view more data
100 Deals associated with Recombinant anti-VEGF humanized monoclonal antibody(Shanghai Fudan Zhangjiang Bio Pharmaceutical Co. Ltd.)
Login to view more data
R&D Status
10 top R&D records. to view more data
Login
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Locally Advanced Lung Non-Squamous Non-Small Cell Carcinoma | Phase 3 | CN | 17 Apr 2020 | |
| Metastatic Non-Squamous Non-Small Cell Lung Carcinoma | Phase 3 | CN | 17 Apr 2020 | |
| Recurrent Lung Non-Squamous Non-Small Cell Carcinoma | Phase 3 | CN | 17 Apr 2020 | |
| Metastatic Colorectal Carcinoma | Discovery | CN | 23 Oct 2019 | |
| Dystrophy, Macular | Discovery | CN | 20 Apr 2016 |
Login to view more data
Clinical Result
Clinical Result
Indication
Phase
Evaluation
View All Results
Login to view more data
Translational Medicine
Boost your research with our translational medicine data.
login
or
Deal
Boost your decision using our deal data.
login
or
Core Patent
Boost your research with our Core Patent data.
login
or
Clinical Trial
Identify the latest clinical trials across global registries.
login
or
Approval
Accelerate your research with the latest regulatory approval information.
login
or
Regulation
Understand key drug designations in just a few clicks with Synapse.
login
or
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free